The group’s principal activity is developed novel small molecule antibiotics that mimic the activity of host defense proteins. The group is seeking to commercialize these antibiotics in a variety of forms to combat drug resistant bacterial infections. The group operates from the United States. In the year 2006, the group’s total revenue was $821 (thousands).
